Evidence map›Paper›PMID 38676754›Full record

ArticleMolecular biotechnology2025

Up-Regulation of MELK Promotes Cell Growth and Invasion by Accelerating G1/S Transition and Indicates Poor Prognosis in Lung Adenocarcinoma.

Qinggan Ni, Yuqing Miao, Xia Li, Zhongbo Yin, Hua Huang, Guanglin Shi, Weirong Shi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Qinggan Ni *Department of Burns and Plastic Surgery, Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, Yancheng, 224000, People's Republic of China.
Yuqing Miao *Department of Respiratory Diseases, The Sixth People's Hospital of Nantong (Affiliated Nantong Hospital of Shanghai University), Nantong, Jiangsu, 226011, People's Republic of China.
Xia Li *Department of General Medicine, Affiliated Hospital of Nantong University, Yancheng Third People's Hospital, Yancheng, 224000, People's Republic of China.
Zhongbo YinDepartment of Pathology, The Sixth People's Hospital of Nantong (Affiliated Nantong Hospital of Shanghai University), Nantong, Jiangsu, 226011, People's Republic of China.
Hua HuangDepartment of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226011, People's Republic of China.
Guanglin ShiDepartment of Respiratory Diseases, The Sixth People's Hospital of Nantong (Affiliated Nantong Hospital of Shanghai University), Nantong, Jiangsu, 226011, People's Republic of China. guanglin1983@hotmail.com.ORCID http://orcid.org/0000-0001-5621-7450
Weirong ShiDepartment of Thoracic Surgery, The Sixth People's Hospital of Nantong (Affiliated Nantong Hospital of Shanghai University), Nantong, Jiangsu, 226011, People's Republic of China. 1192399119@qq.com.
Nantong University · CNXuzhou Medical College · CNYancheng Third People's Hospital · CN

Funding

Nantong Municipal Commission of Health and Family Planning MA2021030
6 · The paper itself

Abstract

Maternal embryonic leucine zipper kinase (MELK) is an oncogene in many tumors, although its contribution to lung adenocarcinoma (LUAD) is unclear. We examined MELK expression in patient LUAD tissue and matched healthy lung tissues. We investigated the connection between MELK expression and tumor differentiation, lymph node metastasis, and patient survival. We downregulated MELK expression using small-hairpin RNA to assess its impact on LUAD cell proliferation, clonogenicity, and invasion. We also investigated the molecular mechanism underlying these effects. MELK expression was significantly heightened in LUAD tissue as opposed to the matching healthy lung tissues. LUAD patients who had MELK overexpression had a worse prognosis. Suppression of MELK hinders proliferation, clonogenicity, and invasion of LUAD cells. The MELK suppression led to the arrest of the cell cycle's G1/S phase by reducing the cyclin E1 and cyclin D expression. Our outcomes manifest that MELK can function as a beneficial prognostic indication and a new therapy target for LUAD. MELK has an essential function in progressing LUAD, manifesting potential as a viable target for therapeutic intervention in this disease management.

Indexed as

Adenocarcinoma of LungLung NeoplasmsProtein Serine-Threonine KinasesAgedCell Line, TumorCell ProliferationCyclin DCyclin EFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm InvasivenessOncogene ProteinsPrognosisCCNE1 protein, humanCyclin DCyclin EMELK protein, humanOncogene ProteinsProtein Serine-Threonine KinasesAdenocarcinoma of lungCell cycleCell proliferationMELKNeoplasm invasiveness

Identifiers

PMID38676754
OpenAlexW4395690486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.